Coronavirus Infection, Covid19, SARS-CoV 2
Conditions
Keywords
melatonin, prevention, covid19, Sars-CoV2, healthcare
Brief summary
There is an urgent need to evaluate interventions that can prevent the infection with SARS-CoV 2 of healthcare workers at risk. Melatonin is an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti-inflammatory and anti-oxidative effects. This randomized controlled trial seeks to evaluate is efficacy as a prophylaxis in healthcare workers exposed to the virus in their clinical practice.
Detailed description
Healthcare workers are at an increased risk of acquiring COVID-19 due to an increased exposure to the virus and global personal protective equipment shortages. Preventing the infection of healthcare workers is critical the current epidemic situation when healthcare systems are under extreme pressure. There is a lack of evidence surrounding potential preventive strategies to decrease the incidence of COVID-19 among healthcare workers. Melatonin, an endogenous hormone involved in circadian rhythm control, is an inexpensive and safe product that has shown protective effects in bacterial and viral infections likely due to its anti-inflammatory and anti-oxidative effects. SARS-CoV 2 seems to relatively spare younger children and those who are infected develop the severe forms of the disease very rarely. Peak melatonin serum levels are higher in younger children and decrease with age. These levels are also higher in women, specially during pregnancy, who also seem to be less affected by the virus when compared to men. The investigators hypothesize that elevating peak melatonin levels to a range similar to that of children by administering 2 mg of melatonin daily might prevent the infection with SARS-CoV 2 among exposed healthcare workers. The investigators also hypothesize that among those who develop the disease melatonin might prevent the more severe forms.
Interventions
DRUGMelatonin 2mg
2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks
DRUGPlacebo oral tablet
Identically looking placebo tablets P.O. before bedtime for 12 weeks
Sponsors
Instituto de Investigación Hospital Universitario La Paz
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Healthcare workers from the public and private Spanish hospital network at risk of SARS-CoV 2 infection * Not having a previous COVID19 diagnosis * Not having experienced COVID19 symptoms from March 1st 2020 until randomization * Understanding the purpose of the trial and not having taken any pre-exposure prophylaxis (PrEP) including HIV PrEP from March 1st 2020 until randomization * Having a negative SARS-CoV 2 CRP before randomization * Having a negative urinary pregnancy test in the previous 7 days for premenopausal women * Premenopausal women and males with premenopausal couples must commit to using a high efficiency anticonceptive method
Exclusion criteria
* HIV infection * Active hepatitis B infection * Renal failure (CrCl \< 60 mL/min/1.73 m2) or need for hemodialysis * Osteoporosis * Myasthenia gravis * Retinitis pigmentosa * Bradycardia (less than 50 bpm) * Weight less than 40 Kg * Treatment with drugs that prolong the QT interval for more than 7 days in the last month before randomization including: azithromycin, cisapride, methadone, droperidol, sotalol, quinidine, clarithromycin, haloperidol... * Hereditary intolerance to galactose, Lapp lactase deficiency or glucose or galactose malabsorption * Treatment with fluvoxamine * Treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone or zaleplon * Pregnancy * Breastfeeding * History of potentially immune derived diseases such as: lupus, Crohn's disease, ulcerative colitis, vasculitis or rheumatoid arthritis * Insulin-dependent diabetes mellitus * Known history of hypersensitivity to the study drug or any of its components * Patients that should not be included in the study at the judgment of the research team
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SARS-CoV 2 infection rate | up to 12 weeks | Number of confirmed (positive CRP) symptomatic infections in each treatment group |
Countries
Spain
Outcome results
None listed